Roy Buchanan analyst JMP

Currently out of the existing stock ratings of Roy Buchanan, 35 are a BUY (94.59%), 2 are a HOLD (5.41%).

Roy Buchanan

Work Performance Price Targets & Ratings Chart

Analyst Roy Buchanan works at JMP with a stock forecast success ratio of 27.78% fulfilled within 68.78 days on average.

Roy Buchanan’s has documented 74 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ENTA, Enanta Pharmaceuticals at 07-May-2024.

Wall Street Analyst Roy Buchanan

Analyst best performing recommendations are on ENTA (ENANTA PHARMACEUTICALS).
The best stock recommendation documented was for ENTA (ENANTA PHARMACEUTICALS) at 11/8/2021. The price target of $77 was fulfilled within 11 days with a profit of $17.24 (18.29%) receiving and performance score of 16.63.

Average potential price target upside

CVAC CureVac NV ENTA Enanta Pharmaceuticals HOOK Hookipa Pharma ARGX argenx NV ADR ABUS Arbutus Biopharma Corp DVAX Dynavax Technologies IBIO Ibio PRDS Pardes Biosciences ANTX AN2 Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

8

$4.31 (116.80%)

20

9 months 5 days ago

4/4 (100%)

$-0.89 (-10.01%)

32

Buy

24

$20.31 (550.41%)

34

1 years 1 months ago

0/5 (0%)

$16.73 (230.12%)

Hold

21

$17.31 (469.11%)

58

1 years 4 months 20 days ago

1/2 (50%)

$12.74 (154.24%)

63

Sell

47

3 years 1 months ago

1/1 (100%)

$-81.95 (-63.55%)

295

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Roy Buchanan is most bullish on?

Potential upside of $9.97 has been obtained for ENTA (ENANTA PHARMACEUTICALS)

Which stock is Roy Buchanan is most reserved on?

Potential downside of -$0 has been obtained for ANTX (AN2 THERAPEUTICS)

What Year was the first public recommendation made by Roy Buchanan?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?